The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
New listings reveal expanded phase 3 programmes for J&J’s Talvey and Amgen’s tarlatamab.
Opdivo plus Yervoy scores a remarkable survival benefit in Checkmate-8HW, whose control arm presents some comparability difficulties.
The first-line liver cancer Emerald-1 trial is positive, but only up to a point.
Skyscraper-08 yields a positive result that – with caveats – looks decent on a cross-trial basis too.
Bristol renews its focus on chronic lymphocytic leukaemia, but rivals haven’t fared so well here.
Three years after licensing in the IAP inhibitor xevinapant Merck KGaA will find out if the deal was worth it.